Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
In a recent transaction reported to the Securities and Exchange Commission, Edward M. Basile, a director at TransMedics Group, Inc. (NASDAQ:TMDX), sold 6,000 shares of the company’s common stock. The shares were sold at a price of $115.63 each, totaling approximately $693,780. The stock, currently trading at $122.11, has shown remarkable momentum with a 30.77% gain in the past week. According to InvestingPro analysis, the stock’s RSI suggests overbought conditions.
The transaction took place on May 9, 2025. Following this sale, Basile’s direct ownership in TransMedics stands at 732 shares. Prior to the sale, Basile exercised stock options to acquire 6,000 shares at a price of $0.70 per share, an action that added $4,200 to his holdings before the subsequent sale. The company, valued at $4.1 billion, maintains strong financial health with a "GREAT" overall score on InvestingPro.
TransMedics Group, Inc., known for its innovative organ transplant systems, continues to be a point of interest for investors monitoring insider activities. The company has demonstrated impressive revenue growth of 64.43% over the last twelve months. For comprehensive insider trading analysis and 18 additional ProTips, visit InvestingPro.
In other recent news, TransMedics Group reported impressive financial results for the first quarter of 2025, with earnings per share (EPS) of $0.70, significantly exceeding the forecasted $0.26. The company’s revenue reached $144 million, surpassing both Oppenheimer’s and consensus estimates of $130 million and $124 million, respectively. U.S. transplant revenue was notably strong, with $139 million, including contributions from liver, heart, and lung transplants. Following these results, Oppenheimer raised its price target for TransMedics to $130, maintaining an Outperform rating. The company has also updated its full-year revenue guidance to a range between $565 million and $585 million, up from the previous range of $530 million to $552 million. This upward revision is attributed to significant share gains in the liver and heart segments. TransMedics continues to focus on expanding its transplant logistics and clinical programs, with plans to launch new heart and lung clinical trials later this year. The company remains confident in its strategic direction, emphasizing its commitment to both top-line growth and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.